The legal action, filed by the firm Levi & Korsinsky under the SueWallSt brand, covers investors who purchased Embecta securities between November 25, 2025, and May 4, 2026. The core of the complaint centers on a $75 million reduction in revenue guidance, which triggered a price drop from $9.25 to $3.90 per share. Plaintiffs argue that management reaffirmed fiscal year 2026 projections of over $1 billion despite knowing that a major customer was abandoning the product and that market volume for insulin delivery devices was shifting toward newer therapies like GLP-1s.
Embecta Investors File Class Action Following 57% Stock Collapse
A federal class action lawsuit now targets Embecta Corp. following a dramatic 57.8% share price collapse that wiped out significant investor value in a single day. The litigation claims the company issued misleading revenue guidance while internal records allegedly showed eroding demand for its core pen needle product line.
According to the lawsuit, pen needles account for roughly 85% of Embecta’s portfolio, making the company’s failure to disclose these specific headwinds particularly damaging. The complaint highlights that $53 million of the total revenue miss originated directly from this segment. Joseph E. Levi, the lead attorney, stated that the case hinges on whether the company’s disclosures met regulatory obligations when facing concentrated customer losses and changing market dynamics. Investors seeking to participate in the suit have until August 17, 2026, to file as lead plaintiffs.
Comments (0)
No comments yet. Be the first!